Fizazi K et al., 2022-04-30: PEACE-1 used a 2×2 factorial design in 1,173 men with de novo metastatic disease; adding abiraterone to ADT with or without docetaxel improved radiographic progression-free survival and overall survival, with grade 3+ adverse events in 63% vs 52% of the docetaxel subgroup.
In the androgen deprivation therapy with docetaxel population (n=355 in both with abiraterone and without abiraterone groups), the HRs were consistent (radiographic progression-free survival 0·50, 99·9% CI 0·34-0·71; p<0·0001; overall survival 0·75, 95·1% CI 0·59-0·95; p=0·017).
Abstract (FINDINGS)
Fizazi K et al., 2022-04-30: PEACE-1 used a 2×2 factorial design in 1,173 men with de novo metastatic disease; adding abiraterone to ADT with or without docetaxel improved radiographic progression-free survival and overall survival, with grade 3+ adverse events in 63% vs 52% of the docetaxel subgroup. Funder: 'FUNDING: Janssen-Cilag, Ipsen, Sanofi, and the French Government.' Conflicts: individual disclosures in the Lancet appendix, not in the abstract; several investigators report Janssen/Sanofi advisory roles. Maker: Janssen-Cilag (abiraterone/Zytiga); docetaxel in the standard-of-care arm is Sanofi's. Comparator: standard of care (ADT with or without docetaxel), open label. Study type: randomized trial.
